Multiple law firms filed a class-action lawsuit against ADMA Biologics, Inc. and its executives. The suit alleges the company committed securities fraud through false and misleading statements.
The complaint claims ADMA engaged in an undisclosed related-party transaction. It further alleges the company utilized channel stuffing to artificially inflate revenue figures.
These actions reportedly created a false impression of the company's financial health and growth. ADMA’s stock price dropped significantly in March 2026 after a short-seller report raised these concerns.